Biocon collaborates with Canada's Juno Pharma for diabetes and obesity treatment

On Friday, October 6, leading biotechnology company Biocon Ltd announced a strategic agreement with Juno Pharmaceuticals, a well-known Canadian specialty pharmaceutical company.

 

The partnership aims to introduce and market Liraglutide, a novel drug-device combination for the treatment and control of type 2 diabetes and obesity.

In accordance with the conditions of the contract, Biocon will be in charge of obtaining regulatory authorization for Liraglutide and then managing its production and supply for the Canadian market.

 

Juno Pharmaceuticals is recognised as one of Canada's rapidly-growing pharmaceutical companies, specialising in the production of high-value generic drugs, complex pharmaceuticals, biosimilars, and other scarce medications, all geared towards enhancing the quality of healthcare in the region.

Mark Mantel, Chief Executive Officer of Juno Pharmaceuticals, said, "Our partnership with Biocon is a significant step in our commitment to provide Canadians with high-quality, affordable medications. We are dedicated to ensuring access to more complex medicines for our patients."

 

Top stories
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read . 02 Aug 2024 . 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read . 02 Aug 2024 . 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read . 02 Aug 2024 . 12:36 PM

Related Blogs
blog-logo

Economy

blog-logo

14 mins read . 08 Nov 2024

Hindustan Unilever History

  • 0 people read
blog-logo

Economy

blog-logo

8 mins read . 08 Nov 2024

What is Fiat Money

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions